Please login to the form below
PD-1 inhibitor
This page shows the latest PD-1 inhibitor news and features for those working in and with pharma, biotech and healthcare.
Bristol Myers Squibb’s Opdivo recommended by NICE for rare gastroesophageal cancers
The PD-1 inhibitor demonstrated a statistically significant benefit in overall survival. ... By attaching to PD-1, Opdivo blocks its action and allows the body’s immune system to continue to attack the gastric, oesophageal or gastro-oesophageal
Latest news
-
Regeneron’s Libtayo granted EC approval for recurrent or metastatic cervical cancer
Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) has been approved by the European Commission (EC) as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease ... Libtayo was the first PD-1 inhibitor to
-
Regeneron’s Libtayo combination granted FDA approval for non-small-cell lung cancer
Regeneron’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) has been approved by the US Food and Drug Administration (FDA) in combination with platinum-based chemotherapy as a first-line treatment for
-
Bristol Myers Squibb’s Opdivo shows promise as adjuvant melanoma treatment
The PD-1 inhibitor demonstrated a statistically significant benefit in recurrence-free survival. ... Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, designed to help the natural T-cell response to cancer, by improving the body’s
-
Bristol Myers Squibb’s Opdivo shows promise as adjuvant melanoma treatment
Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, designed to try to help the natural T-cell response to cancer, by improving the body’s ability to recognise ... In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to
-
Regeneron’s fianlimab/Libtayo combination shows positive results in advanced melanoma treatment
Regeneron has announced the presentation of positive data from multiple expansion cohorts of an initial phase 1 trial for an investigational combination of LAG-3 inhibitor fianlimab and PD-1 inhibitor ... L1 inhibitor (PD-1/PD-L1-naïve) and one of
More from news
Approximately 7 fully matching, plus 292 partially matching documents found.
Latest Intelligence
-
Immuno-oncology in 2019: the rapid evolution continues
cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast.
-
Drug launches to watch in 2019
1 inhibitor Keytruda (pembrolizumab) was backed for cancers harbouring a biomarker known as microsatellite instability-high (MSI-H). ... t the only oral JAK inhibitor developer with its eye on that particular prize.
-
Is China ready for a pharmaceutical gold rush?
The programmed cell death 1 (PD-1) immune checkpoint inhibitor works by restoring the immune system’s ability to fight cancer tumours. ... Competition time. At the same time, Merck’s PD-1 agent, Keytruda, is hot on Opdivo’s heels.
-
Deal Watch January 2017
3, 050. Pieris Pharmaceuti-cals. Servier. Exclusive licence outside USA. PRS 332 PD-1-targeting bispecific checkpoint inhibitor and 4 other candidates. ... 775. BMS | Ono. Merck. Patent settlement. PD-1 antibody Keytruda - (pembrolizumab).
-
Pharma deals in September 2015
taking rights (outside China) to a PD-1 inhibitor (POC ready) from Jaingsu Hengrui Medicine (SHR-1210) for advanced solid tumours paying a modest $25m upfront but up to $770m in ... Acquisition - company. 1, 230. Jiangsu Hengrui Medicine. Incyte.
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- EIT Health marks World Cancer Day with €6m pledge for new healthcare delivery models
- World Cancer Day: encouraging men to put their health first
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Strategic behaviour
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Creabilis names Catherine Moukheibir as chairman of the board
- World Health Organization releases latest set of COVID-19 guidelines
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- MIT researchers develop AI model to detect future lung cancer risk
PMHub
Health Unlimited
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
